Full history for every metric is available with a Kvantra account

Stock profile
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
41.9
History
P/E NTM
33.8
Market cap
9.15B
Currency USD
KvantraRankAbout67
IValue58
IIQuality66
IIIMomentum81
Current price
308.89 USD-2.19%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m00051291389470498
Operating profit$m161228
Net profit$m-32-70-1401189205225232
EPS reported$6.847.37
Operating cashflow per share$6.9410.94
Capex per share$0.410.47
FCF per share$6.5310.47
Free cash flow$m189310
Net debt$m-818-903
Book value equity$m1,2201,436
Book value per share$40.7246.55
Number of sharesm29.9530.84
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx36.0441.91
P/B LTMx5.856.38
P/S LTMx18.3419.47
P/FCF LTMx37.7729.52
EV/EBITDA LTMx33.9232.71
EV/Sales LTMx17.0917.55
Earnings Yield LTM%2.77%2.39%
FCF Yield%2.65%3.39%
Quality
ROE%16.80%17.02%
ROIC%13.09%13.70%
Operating margin%41.45%48.44%
Gross margin%92.61%93.36%
FCF/Sales%48.55%65.97%
Growth and momentum
EPS Growth YoY%+128.00%+10.49%
Sales Growth YoY%+33.94%+25.96%
Net Income Growth YoY%+129.74%+13.20%
FCF Growth%+58.51%+87.26%
Operating Profit Growth%+145.52%+43.89%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx20.2336.11
Net Debt/EBITDAx-2.48-1.80
EBIT/Net interestx--
Net debt/market cap%-11.47%-9.87%
Net debt/Equityx-0.67-0.63
Gross debt/equityx0.010.01

ETFs that hold Krystal Biotech

FundTickerPosition#Weight
Vanguard Russell 2000 Growth ETFVTWG70.57%
Invesco Russell 2000 Dynamic Multifactor ETFOMFS100.93%
L&G Russell 2000 US Small Cap Quality UCITS ETFRTWO.L50.52%
American Century Small Cap Growth Insights ETFACSG50.82%

Funds with Krystal Biotech among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price308.89 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Krystal Biotech, Inc. (KRYS)

KRYS · NASDAQ · Healthcare
308.89 USD-2.19%
Sign up to track this stock
Benchmarks
KvantraRank67
Market cap9.15B
P/E NTM33.8
P/E TTM41.9
KvantraRank?67 / 100
Value
58
Quality
66
Momentum
81
Financialsin USD
20242025TTM2026E
ETFs that hold Krystal Biotech
FundTickerPosition#Weight
Vanguard Russell 2000 Growth ETFVTWG70.57%
Invesco Russell 2000 Dynamic Multifactor ETFOMFS100.93%
L&G Russell 2000 US Small Cap Quality UCITS ETFRTWO.L50.52%
American Century Small Cap Growth Insights ETFACSG50.82%

Funds with Krystal Biotech among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current308.89 USD
Upside
Price consensus
Last year average price target
Current price308.89 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free